

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
13 April 2023 (13.04.2023)



(10) International Publication Number
WO 2023/057975 A1

(51) International Patent Classification:

A61K 47/69 (2017.01) *A61P 35/00* (2006.01)
A61K 47/64 (2017.01) *A61P 31/16* (2006.01)
A61K 47/54 (2017.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2022/059608

(22) International Filing Date:

07 October 2022 (07.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/262,269 08 October 2021 (08.10.2021) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85 Södertälje (SE).

(72) Inventors: **URELLO, Morgan Audrey**; AstraZeneca Pharmaceuticals, LP., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **CHRISTIE, Ronald James**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **VAUGHAN, Hannah**; AstraZeneca Pharmaceuticals, LP., One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **STORM, Peter**; c/o AstraZeneca Intellectual Property, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2023/057975 A1

(54) Title: PEPTIDE DENDRONS AND METHODS OF USE THEREOF



(57) Abstract: The specification relates to peptide dendrons comprising one or more residues derived from a modified lysine of formula (I), pharmaceutical delivery systems comprising these peptide dendrons, pharmaceutical compositions containing them, and to their use in therapy.